B. Metzler seel. Sohn & Co. Holding AG Invests $1.35 Million in Glaukos Co. (NYSE:GKOS)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,339 shares of the medical instruments supplier's stock, valued at approximately $1,347,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Pathstone Holdings LLC grew its holdings in Glaukos by 6.3% in the 3rd quarter. Pathstone Holdings LLC now owns 22,449 shares of the medical instruments supplier's stock worth $2,925,000 after buying an additional 1,326 shares in the last quarter. First Turn Management LLC bought a new position in Glaukos in the 3rd quarter worth approximately $12,520,000. LMR Partners LLP grew its holdings in Glaukos by 12.3% in the 3rd quarter. LMR Partners LLP now owns 36,986 shares of the medical instruments supplier's stock worth $4,819,000 after buying an additional 4,059 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in Glaukos by 3.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 43,152 shares of the medical instruments supplier's stock worth $5,622,000 after buying an additional 1,339 shares in the last quarter. Finally, Natixis Advisors LLC grew its holdings in Glaukos by 1.2% in the 3rd quarter. Natixis Advisors LLC now owns 37,738 shares of the medical instruments supplier's stock worth $4,917,000 after buying an additional 441 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Performance

GKOS stock opened at $144.00 on Friday. Glaukos Co. has a 1 year low of $59.22 and a 1 year high of $146.09. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a fifty day simple moving average of $132.05 and a 200 day simple moving average of $123.31.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. The firm had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business's quarterly revenue was up 23.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.50) EPS. As a group, research analysts expect that Glaukos Co. will post -1.96 EPS for the current fiscal year.

Insider Buying and Selling

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares of the company's stock, valued at $4,225,345.12. This represents a 8.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. The trade was a 2.18 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. BTIG Research increased their price target on Glaukos from $131.00 to $139.00 and gave the company a "buy" rating in a research note on Wednesday, August 28th. Needham & Company LLC increased their price target on Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a research note on Thursday, August 1st. Truist Financial boosted their price objective on Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Wells Fargo & Company lifted their price objective on shares of Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Finally, Stifel Nicolaus raised their price objective on Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and a consensus target price of $134.55.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.